Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders
AssigneeGene Vector Technologies (GVT)
InventorAriella OPPENHEIM
Life of this patent
Estimating the term…
Abstract
The present invention relates to viral capsid proteins, as a medicament for the treatment of a pathologic disorder. More particularly, the invention relates to the viral capsid proteins VP1, VP2 and VP3, preferably, the SV40 VP1 or any peptide, fragment, mutant, derivative and mixtures thereof or of virus-like particles (VLP's) comprising the same, as the active ingredient in compositions for the treatment of pathologic disorders, preferably disorders associated with inactivation of cellular proteins involved with quality control processes, particularly, chaperones. The invention further provides methods for the treatment of such disorders and the use of the SV40 capsid proteins for the preparation of pharmaceutical compositions.
Claims35
A method for treatment of a pathologic disorder comprising a step of administering to a subject in need thereof a therapeutically-effective amount of at least one viral capsid protein or any peptide, mutant or fragment thereof, or of virus-like particles (VLPs) comprising at least one capsid protein or any peptide, mutant or fragment thereof, or of a composition comprising the same.
A method for treatment of a pathologic disorder comprising a step of administering to a subject in need thereof a therapeutically-effective amount of at least one SV40 VP1 capsid protein or a 65 amino acid truncated mutant thereof deleted in its carboxy terminal arm or of virus-like particles (VLPs) or any pentamers comprising at least one SV40 VP1 capsid protein or said mutant, or of a composition comprising the same.
A method for treatment of a pathologic disorder comprising a step of administering to a subject in need thereof a therapeutically-effective amount of at least one SV40 VP1 capsid protein or of a composition comprising the same.
A method for treatment of a pathologic disorder comprising a step of administering to a subject in need thereof a therapeutically-effective amount of at least one virus-like particle (VLP) or pentamer comprising an SV40 VP1 capsid protein, or of a composition comprising the same.
A method for rescuing cells from oxidative stress or apoptosis, and inducing survival pathway in said cells, comprising a step of contacting cells undergoing oxidative stress or apoptotic process, with an effective amount of at least one viral capsid protein or any peptide, mutant or fragment thereof or of VLP's comprising said viral capsid protein or any peptide, mutant or fragment thereof, or of a composition comprising the same.
A pharmaceutical composition for treatment of a pathologic disorder comprising as an active ingredient a therapeutically-effective amount of at least one viral capsid protein or any peptide, mutant or fragment thereof or of virus-like particles (VLPs) comprising at least one capsid protein or any peptide, mutant, derivative or fragment thereof.
A pharmaceutical composition for treatment of a pathologic disorder consisting essentially of as an active ingredient a therapeutically-effective amount of at least one SV40 VP1 capsid protein or a 65 amino acid truncated mutant thereof deleted in its carboxy terminal arm or of virus-like particles (VLPs) comprising at least one SV40 VP1 capsid protein or said mutant, or of pentamers comprising said SV40 VP1 or said mutant said composition further comprising a pharmaceutically-acceptable carrier.
A pharmaceutical composition consisting essentially of an SV40 VP1 capsid protein, as an active ingredient and a pharmaceutically-acceptable carrier.
Dependencies are inferred from the claim text.